Premium
Pharmacotherapy for Depressed Pregnant Women: Overcoming Obstacles to Gathering Essential Data
Author(s) -
Wisner K L,
Appelbaum P S,
Uhl K,
Goldkind S F
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.160
Subject(s) - clinical pharmacology , pharmacotherapy , antidepressant , offspring , pregnancy , medicine , data collection , psychiatry , drugs in pregnancy , family medicine , intensive care medicine , psychology , pharmacology , fetus , biology , anxiety , statistics , mathematics , genetics
Approximately 3% of pregnant women take antidepressant medications. Information on the impact of antidepressants on short‐ and long‐term maternal and offspring outcomes is highly desirable but neglected. The position that the dearth of treatment information is of greater concern than the risks to pregnant subjects involved in medical research is gaining support. Mandating the collection of reproductive outcome data in exposed childbearing women is an overdue step toward societal responsibility to our most vulnerable members. Clinical Pharmacology & Therapeutics (2009) 86 4, 362–365. doi: 10.1038/clpt.2009.160